Skip to main content
. 2017 Oct 10;8(60):101832–101846. doi: 10.18632/oncotarget.21762

Figure 2.

Figure 2

(A) Disease-free survival of patients receiving either bevacizumab or cetuximab in the CCRT treatment protocol. (B) Subset survival analysis regarding the influence of k-ras status on disease-free survival in bevacizumab- treated patients, in comparison with cetuximab- treated patients.